Actinomycosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Changes made per Mahshid's request) |
||
| (4 intermediate revisions by 4 users not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
[[Antibiotics]] are the main stay of treatment in actinomycosis. The exact [[antibiotic]] regimen depends on the site of [[infection]], severity of [[disease]], and the patient’s response to treatment. For [[cervicofacial actinomycosis]], [[Ampicillin]] is administered followed by [[Penicillin V]]. Patients with more extensive disease may require surgery. | |||
==Medical therapy== | |||
===Antimicrobial regimen=== | ===[[Antimicrobial|Antimicrobial regimen]]=== | ||
* 1. '''Actinomyces species including A. israeli'''<ref>{{cite book | last = Bennett | first = John | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Elsevier/Saunders | location = Philadelphia, PA | year = 2015 | isbn = 978-1455748013 }}</ref> | * 1. '''Actinomyces species including [[Actinomyces israelii|A. israeli]]'''<ref>{{cite book | last = Bennett | first = John | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Elsevier/Saunders | location = Philadelphia, PA | year = 2015 | isbn = 978-1455748013 }}</ref> | ||
:* Preferred regimen: [[Penicillin]] 3-4 MU IV q4h for 2-6 weeks {{then}} [[Penicillin V]] 2-4 g/day PO | :* Preferred regimen: [[Penicillin]] 3-4 MU IV q4h for 2-6 weeks {{then}} [[Penicillin V]] 2-4 g/day PO QID for 6-12 months | ||
:* Alternative regimen (1): [[Erythromycin]] 500-1000 mg IV q6h {{or}} 500 mg PO | :* Alternative regimen (1): [[Erythromycin]] 500-1000 mg IV q6h {{or}} 500 mg PO QID | ||
:* Alternative regimen (2): [[Tetracyclin]] 500 mg PO | :* Alternative regimen (2): [[Tetracyclin]] 500 mg PO QID | ||
:* Alternative regimen (3): [[Doxycycline]] 100 mg IV q12h {{or}} 100 mg PO | :* Alternative regimen (3): [[Doxycycline]] 100 mg IV q12h {{or}} 100 mg PO BID | ||
:* Alternative regimen (4): [[Clindamycin]] 900 mg IV q8h {{or}} 300-450 mg PO | :* Alternative regimen (4): [[Clindamycin]] 900 mg IV q8h {{or}} 300-450 mg PO QD | ||
:* Alternative regimen (5): [[Minocycline]] 100 mg IV q12h {{or}} 100 mg | :* Alternative regimen (5): [[Minocycline]] 100 mg IV q12h {{or}} 100 mg POBID | ||
* 2. '''Cervico-facial actinomycosis'''<ref name="pmid21990282">{{cite journal| author=Wong VK, Turmezei TD, Weston VC| title=Actinomycosis. | journal=BMJ | year= 2011 | volume= 343 | issue= | pages= d6099 | pmid=21990282 | doi=10.1136/bmj.d6099 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21990282 }} </ref> | * 2. '''[[Cervicofacial actinomycosis|Cervico-facial actinomycosis]]'''<ref name="pmid21990282">{{cite journal| author=Wong VK, Turmezei TD, Weston VC| title=Actinomycosis. | journal=BMJ | year= 2011 | volume= 343 | issue= | pages= d6099 | pmid=21990282 | doi=10.1136/bmj.d6099 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21990282 }} </ref> | ||
:* Preferred regimen: [[Ampicillin]] 50 mg/kg/day IV q8h (4-6 weeks) <u>'''THEN'''</u> [[Penicillin V]] 2-4 g/day PO q6h (3-6 months) | :* Preferred regimen: [[Ampicillin]] 50 mg/kg/day IV q8h (4-6 weeks) <u>'''THEN'''</u> [[Penicillin V]] 2-4 g/day PO q6h (3-6 months) | ||
:* Alternative regimen: [[Penicillin G]] 10-20 MU/day IV q6h (4-6 weeks) <u>'''THEN'''</u> [[Penicillin V]] 2-4 g/day PO q6h (3-6 months) | :* Alternative regimen: [[Penicillin G]] 10-20 MU/day IV q6h (4-6 weeks) <u>'''THEN'''</u> [[Penicillin V]] 2-4 g/day PO q6h (3-6 months) | ||
:* Note: In patients allergic to [[Penicillin]], consider [[Doxycycline]], [[Clindamycin]], or [[Erythromycin]]. | :* Note: In patients allergic to [[Penicillin]], consider [[Doxycycline]], [[Clindamycin]], or [[Erythromycin]]. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
| Line 38: | Line 40: | ||
[[Category:Bacterial diseases]] | [[Category:Bacterial diseases]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Overview complete]] | [[Category:Overview complete]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category: Infectious Disease Project]] | [[Category: Infectious Disease Project]] | ||
Latest revision as of 16:18, 18 September 2017
|
Actinomycosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Actinomycosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Actinomycosis medical therapy |
|
Risk calculators and risk factors for Actinomycosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Antibiotics are the main stay of treatment in actinomycosis. The exact antibiotic regimen depends on the site of infection, severity of disease, and the patient’s response to treatment. For cervicofacial actinomycosis, Ampicillin is administered followed by Penicillin V. Patients with more extensive disease may require surgery.
Medical therapy
Antimicrobial regimen
- 1. Actinomyces species including A. israeli[1]
- Preferred regimen: Penicillin 3-4 MU IV q4h for 2-6 weeks THEN Penicillin V 2-4 g/day PO QID for 6-12 months
- Alternative regimen (1): Erythromycin 500-1000 mg IV q6h OR 500 mg PO QID
- Alternative regimen (2): Tetracyclin 500 mg PO QID
- Alternative regimen (3): Doxycycline 100 mg IV q12h OR 100 mg PO BID
- Alternative regimen (4): Clindamycin 900 mg IV q8h OR 300-450 mg PO QD
- Alternative regimen (5): Minocycline 100 mg IV q12h OR 100 mg POBID
- Preferred regimen: Ampicillin 50 mg/kg/day IV q8h (4-6 weeks) THEN Penicillin V 2-4 g/day PO q6h (3-6 months)
- Alternative regimen: Penicillin G 10-20 MU/day IV q6h (4-6 weeks) THEN Penicillin V 2-4 g/day PO q6h (3-6 months)
- Note: In patients allergic to Penicillin, consider Doxycycline, Clindamycin, or Erythromycin.
References
- ↑ Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455748013.
- ↑ Wong VK, Turmezei TD, Weston VC (2011). "Actinomycosis". BMJ. 343: d6099. doi:10.1136/bmj.d6099. PMID 21990282.
de:Aktinomykose gl:Actinomicose hr:Aktinomikoza nl:Actinomycose sr:Актиномикоза fi:Aktinomykoosi uk:Актиномікоз